EpimAb
易慕峰
EpimAb is a Chinese cell-therapy company developing solid-tumor and in vivo CAR-T approaches. In early 2026 it raised a nearly ¥200 million Pre-IPO round led by Gaorong Capital and others, positioning it toward a public listing . The company traces back to a ZhenFund angel investment, and in 2025 it was recognized both at the New Drug Founders Annual Meeting's "Decade" gala for innovation and on the Forbes Asia 100 Companies to Watch list . elsewhere's corpus does not cover its founding date, team background, or pipeline specifics beyond this financing and award trajectory.
AI-generated — may contain errors, please verify.
Coverage
Rongbao | Karl Dynamics, Aerofugia, StarsComm, and ImmuPeak Kick Off the Year with Major Funding Rounds
Leading the industry into a new era.
高榕创投·Beyond the Set Trajectory | Z News
We look back at the "highlight moments" of the past month and invite you to witness the growth of our portfolio companies and what's new at ZhenFund.
真格基金·Venture Where No One Has Gone Before | Z News
July is drawing to a close, and we invite you to join us in witnessing the growth of our portfolio companies and what's new at ZhenFund.
真格基金·
